Ultragenyx Pharmaceutical Inc. — FY 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. The filing also reports unaudited fourth-quarter results. Ultragenyx is a clinical-stage biopharmaceutical company developing treatments for rare and ultra-rare diseases; it had no approved products or product-sales revenue.
Financial performance and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $46.0 million | $27.8 million |
| General and administrative expense | $10.8 million | $4.5 million |
| Total operating expenses | $56.8 million | $32.3 million |
| Net loss | $59.8 million | $35.1 million |
| Net loss per share attributable to common stockholders | $2.25 | $14.87 |
| Cash used in operating activities | $44.6 million | $31.2 million |
| Cash, cash equivalents and short-term investments at year-end | $187.5 million | $53.4 million |
| Working capital at year-end | $180.9 million | $49.3 million |
- Fourth-quarter 2014 operating expenses were $16.9 million; net loss was $16.7 million and net loss per share was $0.52.
- Operating cash outflow increased as development spending expanded. Investing activities used $123.4 million, principally reflecting purchases of short-term investments; financing activities provided $185.0 million, mainly from the 2014 public offerings.
- Total liabilities were $13.0 million at year-end, including $12.5 million of current liabilities. The filing reports no debt balance. No operating or profit margins are meaningful because the company had no revenue.
Material changes and business progress
- Compared with 2013, R&D expense rose 65% and G&A expense rose 143%; net loss increased by $24.7 million. R&D growth reflected activity across the pipeline, including clinical studies, manufacturing and related development work.
- The company initiated a Phase 3 global study of rhGUS (UX003) for MPS 7 in December 2014. It completed enrollment of 36 patients in the KRN23 pediatric XLH Phase 2 study late in 2014.
- Triheptanoin (UX007) studies continued in LC-FAOD and Glut1 deficiency syndrome. The LC-FAOD Phase 2 study was fully enrolled; Glut1 DS enrollment criteria were expanded to include patients with absence seizures.
- SA-ER (UX001) remained in an extension study for HIBM. Phase 2 results showed a dose-related upper-extremity muscle-strength signal, while the higher 12-gram dose did not suggest a clinically meaningful advantage over six grams.
- rhPPCA (UX004) for galactosialidosis remained in preclinical development.
Outlook, risks and other notable items
- Management expected existing resources, including proceeds from a February 2015 offering, to fund current operations into 2018. That offering generated approximately $174.5 million in net proceeds after year-end; further capital may still be needed to obtain approvals and commercialize products.
- Management expected losses and R&D spending to continue increasing as programs advance. Planned milestones included KRN23 pediatric data in the first half of 2015, triheptanoin interim data in the second half of 2015, a KRN23 adult Phase 2b study in the second half of 2015, and a SA-ER Phase 3 study and planned EU conditional-approval filing in the second half of 2015. These are expectations, not assured outcomes.
- Key risks include clinical and regulatory uncertainty, small and difficult-to-identify patient populations, reimbursement and pricing uncertainty, intellectual-property limits, and dependence on partners and contract manufacturers. Several candidates rely on single-source suppliers; KHK controls KRN23 supply and has significant development and commercialization responsibilities in major territories.
- There were no material legal proceedings. Future minimum operating lease payments were $5.7 million at December 31, 2014; the filing also describes potential milestone and royalty obligations under license agreements. Product-liability insurance was $10 million per incident and in aggregate.
- The company disclosed a nonmaterial correction to interim cash-flow classifications related to deferred IPO offering costs. It stated the correction did not affect net cash used in investing activities, net increase in cash, or net loss per share.
Important facts for investors to verify
- Whether clinical and regulatory milestones occur on the stated timelines, and whether study results support approval.
- Whether the projected cash runway remains adequate as trial, manufacturing and commercialization costs rise.
- Supply continuity, capacity and cost from single-source manufacturers, especially for KRN23 and SA-ER.
- Patient prevalence, eligible treatment populations, pricing, reimbursement and commercial rights by territory.
- The terms and potential financial impact of license milestones, royalties, and the KHK collaboration.